Antonelli Tiziana, Tomasini Maria Cristina, Mazza Roberta, Fuxe Kjell, Gaetani Silvana, Cuomo Vincenzo, Tanganelli Sergio, Ferraro Luca
Department of Clinical and Experimental Medicine, University of Ferrara, Ferrara, Italy.
J Pharmacol Exp Ther. 2009 May;329(2):708-17. doi: 10.1124/jpet.109.150649. Epub 2009 Feb 5.
The effects of treatments with cannabinoid (CB)(1) and cholecystokinin (CCK)(2) receptor agonists and antagonists, as well as compounds that enhance endocannabinoid signaling by inhibiting degradation, e.g., the fatty acid amide hydrolase inhibitor 3'-carbamoyl-biphenyl-3-yl-cyclohexylcarbamate (URB597) or the endocannabinoid reuptake inhibitor (5Z,8Z,11Z,14Z)-N-(3-furanylmethyl)-5,8,11,14-eicosatetraenamide (UCM707), were studied both on spontaneous and electrically evoked [(3)H]GABA efflux from rat cerebral cortex cell cultures. The CCK(2) receptor agonist CCK-8S, the CB(1) receptor agonist (R)-(+)-[2,3-dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-naphthalenylmethanone (WIN55,212-2), URB597, UCM707, the CB(1) receptor antagonist N-piperidino-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-3-pyrazole-carboxamide (SR141716A), and the CCK(2) receptor antagonist 2-[2-(5-Br-1H-indol-3-yl)ethyl]-3-[3-(1-methylethoxy)phenyl]-4-(3H)-quinazolinone (LY225910) did not affect spontaneous [(3)H]GABA efflux. CCK-8S concentration-dependently increased electrically evoked [(3)H]GABA overflow, and this effect was prevented by LY225910. WIN55,212-2, URB597, and UCM707 induced a reduction of electrically evoked [(3)H]GABA overflow. This reduction was counteracted by SR141716A. When CCK-8S and one of cannabinoid-interfering compounds were simultaneously added, at concentrations by themselves ineffective, to the superfusion medium, an enhancement in electrically evoked [(3)H]GABA efflux was observed. This increase was counteracted by either SR141716A or LY225910 as well as by the inhibitor of protein kinase C, (1R)-2-[12-[(2R)-2-(benzoyloxy)propyl]-3,10-dihydro-4,9-dihydroxy-2,6,7,11-tetramethoxy-3,10-dioxo-1-perylenyl]-1-methylethylcarbonic acid 4-hydroxyphenyl ester (calphostin C). These results indicate that CB(1) and CCK(2) receptors modulate, in an opposing way, electrically evoked [(3)H]GABA efflux from rat cerebral cortex cell cultures. The existence of a CB(1)/CCK(2) receptor heteromer on cortical GABA terminals, with a possible relevance for cortical GABA transmission and anxiety, is postulated.
研究了大麻素(CB)(1)和胆囊收缩素(CCK)(2)受体激动剂与拮抗剂的治疗效果,以及通过抑制降解来增强内源性大麻素信号传导的化合物的效果,例如脂肪酸酰胺水解酶抑制剂3'-氨基甲酰基-联苯-3-基-环己基氨基甲酸酯(URB597)或内源性大麻素再摄取抑制剂(5Z,8Z,11Z,14Z)-N-(3-呋喃基甲基)-5,8,11,14-二十碳四烯酰胺(UCM707),这些研究均针对大鼠大脑皮层细胞培养物中自发的和电诱发的[³H]GABA流出。CCK(2)受体激动剂CCK-8S、CB(1)受体激动剂(R)-(+)-[2,3-二氢-5-甲基-3-(4-吗啉基甲基)吡咯并[1,2,3-de]-1,4-苯并恶嗪-6-基]-1-萘基甲酮(WIN55,212-2)、URB597、UCM707、CB(1)受体拮抗剂N-哌啶基-5-(4-氯苯基)-1-(2,4-二氯苯基)-4-甲基-3-吡唑甲酰胺(SR141716A)以及CCK(2)受体拮抗剂2-[2-(5-溴-1H-吲哚-3-基)乙基]-3-[3-(1-甲乙氧基)苯基]-4-(3H)-喹唑啉酮(LY225910)均不影响自发的[³H]GABA流出。CCK-8S以浓度依赖性方式增加电诱发的[³H]GABA溢出,且LY225910可阻止此效应。WIN55,212-2、URB597和UCM707可使电诱发的[³H]GABA溢出减少。这种减少被SR141716A抵消。当将CCK-8S与一种本身无效浓度的大麻素干扰化合物同时添加到灌流培养基中时,可观察到电诱发的[³H]GABA流出增强。这种增加被SR141716A或LY225910以及蛋白激酶C抑制剂(1R)-2-[12-[(2R)-2-(苯甲酰氧基)丙基]-3,10-二氢-4,9-二羟基-2,6,7,11-四甲氧基-3,10-二氧代-1-苝基]-1-甲基乙基碳酸4-羟基苯基酯(钙磷蛋白C)抵消。这些结果表明,CB(1)和CCK(2)受体以相反的方式调节大鼠大脑皮层细胞培养物中电诱发的[³H]GABA流出。推测在皮质GABA终末存在CB(1)/CCK(..)受体异聚体,这可能与皮质GABA传递和焦虑有关。